{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:31:19Z","timestamp":1782603079929,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013767","name":"ACEA Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.cllc.2020.05.012","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T11:50:37Z","timestamp":1590148237000},"page":"e329-e335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["PD-1\/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5308-0014","authenticated-orcid":false,"given":"Maggie","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha P.","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2020.05.012_bib1","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2020.05.012_bib2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.athoracsur.2014.04.040","article-title":"Women with malignant pleural mesothelioma have a threefold better survival rate than men","volume":"98","author":"Taioli","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cllc.2020.05.012_bib3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/JTO.0b013e3181f1903e","article-title":"Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population","volume":"5","author":"Flores","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.21037\/tlcr.2017.06.01","article-title":"Novel systemic therapy against malignant pleural mesothelioma","volume":"6","author":"Mancuso","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2020.05.012_bib5","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.12688\/f1000research.15512.2","article-title":"Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort","volume":"7","author":"Amin","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.cllc.2020.05.012_bib6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","article-title":"FDA drug approval summaries: pemetrexed (Alimta)","volume":"9","author":"Hazarika","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2020.05.012_bib7","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1078-0432.982.11.3","article-title":"Pemetrexed in malignant pleural mesothelioma","volume":"11","author":"Hazarika","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2020.05.012_bib9","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2020.05.012_bib11","first-page":"426","article-title":"Acute injury and regeneration of the mesothelium in response to asbestos fibers","volume":"128","author":"Moalli","year":"1987","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cllc.2020.05.012_bib12","first-page":"271","article-title":"Inflammation generating potential of long and short fibre amosite asbestos samples","volume":"46","author":"Donaldson","year":"1989","journal-title":"Br J Ind Med"},{"key":"10.1016\/j.cllc.2020.05.012_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cllc.2020.05.012_bib14","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cllc.2020.05.012_bib15","first-page":"1007","article-title":"Lymphocytic infiltration of pleural mesothelioma and its significance for survival","volume":"61","author":"Leigh","year":"1982","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.cllc.2020.05.012_bib16","doi-asserted-by":"crossref","first-page":"e106742","DOI":"10.1371\/journal.pone.0106742","article-title":"Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma","volume":"9","author":"Cornelissen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2020.05.012_bib17","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.05.012_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib19","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2020.05.012_bib20","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21037\/tlcr.2017.05.02","article-title":"Immunotherapy for malignant pleural mesothelioma: current status and future directions","volume":"6","author":"Dozier","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2020.05.012_bib22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.cllc.2020.05.012_bib23","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s11033-019-04715-9","article-title":"Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma","volume":"46","author":"Sobhani","year":"2019","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.cllc.2020.05.012_bib24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3390\/cancers12020361","article-title":"Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: correlation with survival","volume":"12","author":"Chiarucci","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2020.05.012_bib25","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1200\/JCO.2017.35.15_suppl.8557","article-title":"Biomarkers of pembrolizumab (P) activity in mesothelioma (MM): results from a phase II trial","volume":"35","author":"Kindler","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib26","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2020.05.012_bib28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2020.05.012_bib32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib33","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2020.05.012_bib35","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2020.05.012_bib36","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/j.jtho.2018.08.276","article-title":"DREAM\u2014a phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: final result","volume":"13","author":"Nowak","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 5","key":"10.1016\/j.cllc.2020.05.012_bib37","article-title":"Multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Ann Oncol"},{"issue":"1 suppl","key":"10.1016\/j.cllc.2020.05.012_bib38","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","article-title":"A\u00a0phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopsies","volume":"12","author":"Quispel-Janssen","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2020.05.012_bib39","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2020.05.012_bib40","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2018.36.15_suppl.8503","article-title":"DREAM: a phase II study of durvalumab with first line chemotherapy in mesothelioma\u2014first results","volume":"36","author":"Nowak","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.05.012_bib41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","article-title":"CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial","volume":"19","author":"Fennell","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.cllc.2020.05.012_bib42","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1016\/j.cllc.2018.05.001","article-title":"A\u00a0phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol","volume":"19","author":"Fujimoto","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2020.05.012_bib43","doi-asserted-by":"crossref","first-page":"TPS8581","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8581","article-title":"CheckMate 743: a phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma","volume":"35","author":"Zalcman","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420301522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420301522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:13:50Z","timestamp":1761506030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730420301522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1525730420301522"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2020.05.012","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-1\/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2020.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}